1 results match your criteria: "Clatterbridge Cancer Centre-The Linda McCartney Centre[Affiliation]"
The impact of the 21-gene recurrence score (Oncotype DX) on concordance of adjuvant therapy decision making as measured by the Liverpool Systemic Therapy Adjuvant Decision Tool.
Breast
April 2019
The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, CH63 4JY, UK; The University of Liverpool, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, L69 3GE, UK; Liverpool and Merseyside Academic Breast Unit, Clatterbridge Cancer Centre-The Linda McCartney Centre, Liverpool, L7 8XP, UK. Electronic address:
Purpose: The 21-gene recurrence score (Oncotype DX) (RS) informs systemic therapy decision making in ER-positive HER2-negative early breast cancer (BC). To date no study has described the more nuanced discussions that take place regarding systemic therapy or the impact of the RS on concordance in such decision making. Here we utilized a novel decision making tool to assess the impact of the RS on decision making as well as concordance of treatment recommendations.
View Article and Find Full Text PDF